Bucetin

Summary

Bucetin (CHEMBL1697856) is an approved small molecule (ATC N02BE74); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02BE74 (+2 more)
• Indications: 2 conditions
• Chemistry: 223.27 Da · C12H17NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697856
Name	Bucetin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	14130
ATC	N02BE74, N02BE04, N02BE54
Molecular formula	C12H17NO3
Molecular weight	223.27
InChIKey	LIAWQASKBFCRNR-UHFFFAOYSA-N

SMILES: CCOC1=CC=C(C=C1)NC(=O)CC(C)O

IUPAC name: N-(4-ethoxyphenyl)-3-hydroxybutanamide

Also known as: Betadid, Bucetin, Bucetina, Bucetine, NSC-320045, NSC-759243, bucetin, SID170465885, SID144205887, SID144213206, SID144209014, BUCETIN

Patent coverage: 378 distinct patent families (1,567 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).